The Biomarkers Definitions Working Group defines a clinical endpoint as a variable that
reflects how a patient feels, functions, or survives (5, 6). The past 3 decades of IPF clinical …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease
severity and rate of progression. The need for a reliable, sensitive, and objective biomarker …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease
severity and rate of progression. The need for a reliable, sensitive, and objective biomarker …

Computed tomographic biomarkers in idiopathic pulmonary fibrosis: The future of quantitative
analysis IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie Tipologia …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease
severity and rate of progression. The need for a reliable, sensitive, and objective biomarker …

in the absence of an ideal endpoint such as mortality, the substitution of a validated
biomarker for a clinical endpoint (ie, a surrogate endpoint) that can reliably predict the effect …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with great variability in disease
severity and rate of progression. The need for a reliable, sensitive, and objective biomarker …

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of
Quantitative Analysis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …